分析莫西沙星治疗成人支原体肺炎的临床效果

Analysis of the Clinical Effect of Moxifloxacin in the Treatment of Adult Mycoplasma Pneumoniae Pneumonia

目的评价莫西沙星治疗成人支原体肺炎的临床效果与安全性,以促进成人支原体肺炎症状体征改善,为支原体肺炎患者的用药治疗工作提供参考。方法选择该院呼吸内科2018年5月—2019年7月期间收治的成人支原体肺炎患者,总计96例。采取随机法,进行96例成人支原体肺炎患者分组治疗,即试验1组(n=48)、试验2组(n=48)。试验1组48例成人支原体肺炎患者采取莫西沙星治疗,试验2组48例成人支原体肺炎患者采取阿奇霉素治疗。对比试验1组与试验2组成人支原体肺炎患者治疗总有效率、不良反应发生率、退热时间、止咳时间、住院时间。结果试验1组与2组成人支原体肺炎患者治疗后总有效率(95.83%vs 79.16%)(χ~2=6.095,P=0.014)、不良反应发生率(4.17%vs 25.00%)(χ~2=8.362,P=0.004)、退热时间[(1.05±0.30)d vs(1.80±0.50)d(t=8.911,P=0.000)]、止咳时间[(4.50±1.05)d vs(7.30±1.30)d(t=11.609,P=0.000)]、住院时间[(11.50±1.05)d vs(13.30±1.30)d(t=7.463,P=0.000)]比较,差异有统计学意义(P<0.05)。结论对比阿奇霉素治疗,莫西沙星治疗成人支原体肺炎加速了患者退热、止咳,缩短了患者住院时间,且用药安全性更高、治疗效果更好,是治疗成人支原体肺炎的优选药物。

Objective To evaluate the clinical efficacy and safety of moxifloxacin in the treatment of adult mycoplasma pneumonia,in order to promote the improvement of the signs and symptoms of mycoplasma pneumonia in adults,and to provide reference for the treatment of patients with mycoplasma pneumonia.Methods A total of 96 patients with adult Mycoplasma pneumonia treated in the department of respiratory medicine from May 2018 to July 2019 were selected.Randomized method was used to treat 96 adult patients with Mycoplasma pneumonia in two groups,that is,test group 1(n=48)and test group 2(n=48).48 adult patients with Mycoplasma pneumonia in the test group were treated with moxifloxacin,and 48 adult patients with mycoplasma pneumonia in the test group were treated with azithromycin.The total effective rate,incidence of adverse reactions,antipyretic time,antitussive time,and length of hospitalization of patients with Mycoplasma pneumoniae in test group 1 and test 2 were compared.Results The total effective rate(95.83%vs 79.16%)(χ2=6.095,P=0.014)and the incidence of adverse reactions(4.17%vs 25.00%)(χ2=8.362,P=0.004)in patients with test group 1 and group 2 were treated with Mycoplasma pneumoniae,Antipyretic time[(1.05±0.30)d vs(1.80±0.50)d(t=8.911,P=0.000)],coughing time[(4.50±1.05)d vs(7.30±1.30)d(t=11.609,P=0.000)],hospitalization time[(11.50±1.05)d vs(13.30±1.30)d(t=7.463,P=0.000)],and the difference was statistically significant(P<0.05).Conclusion Compared with azithromycin treatment,moxifloxacin treatment of adult mycoplasma pneumonia can accelerate fever and cough,shorten the length of hospital stay,and has better safety and better treatment effect.It is the preferred drug for the treatment of adult mycoplasma pneumonia.